Actively Recruiting
CENP-V as a Diagnostic Marker of Damage in Human Oocytes A Study Comparing Oocyte Protein Levels in Women of Advanced Maternal Age and Controls
Led by Vida Recoletas Sevilla · Updated on 2025-01-23
160
Participants Needed
1
Research Sites
116 weeks
Total Duration
On this page
Sponsors
V
Vida Recoletas Sevilla
Lead Sponsor
U
University of Seville
Collaborating Sponsor
AI-Summary
What this Trial Is About
Researchers are investigating the protein CENP-V in human oocytes to understand its role as a potential diagnostic marker for age-related and procedure-related damage. The study focuses on oocytes from women of advanced maternal age (AMA) and compares them with controls, aiming to assess how CENP-V expression levels relate to oocyte quality and survival after vitrification and thawing. This research addresses fertility challenges linked to aging and aims to improve prediction of oocyte viability. The study analyzes immature human oocytes that would otherwise be discarded, from AMA patients, controls, and those undergoing vitrification and thawing. CENP-V protein levels will be measured both in fresh oocytes and after thawing procedures. Mature oocytes used for patient treatment will not be included; only immature or donated mature oocytes are studied. The study is designed as a prospective, unicentric, descriptive, and cross-sectional investigation. Participants will undergo controlled ovarian stimulation and oocyte retrieval, with immature oocytes collected for analysis. Researchers will measure CENP-V levels from enrollment through oocyte retrieval over two days. The study also correlates CENP-V expression with aneuploidy rates in blastocysts from AMA patients. Data will help assess oocyte damage from aging or vitrification, aiming to establish CENP-V as a biomarker for oocyte quality and survival rates after thawing.
CONDITIONS
Official Title
CENP-V As a Potential Diagnostic Marker of Damage in Human Oocytes
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients aged 36-45 years with advanced maternal age undergoing controlled ovarian stimulation
- Patients aged 18-45 years who have undergone oocyte vitrification and will thaw oocytes in the study
- Patients aged 36-45 years with vitrified/thawed oocytes and advanced maternal age
- Patients aged 18-35 years with vitrified/thawed oocytes without advanced maternal age
- Control patients and donors aged 18-35 years with normal fertility undergoing ovarian stimulation and oocyte collection
You will not qualify if you...
- Patients with conditions affecting oocyte quality such as polycystic ovary syndrome (PCO), premature ovarian insufficiency (POI), endometriosis, or cancer
- Patients or donors who had oocyte cryopreservation by slow freezing technique
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Vida Recoletas Sevilla S.L.
Seville, SEVILLA, Spain, 41009
Actively Recruiting
Research Team
E
ESTHER SANTAMARÍA LÓPEZ
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here